Clinical trial NCT05148091: The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults
Official title: A Randomized, Double-blind, Placebo-controlled Phase Ⅰ/Ⅱ Clinical Study to Evaluate the Safety, Tolerability and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Unvaccinated Against COVID-19
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: COVID-19
Lead sponsor: Sinocelltech Ltd.
Sponsor class: INDUSTRY
First posted: 2021-12-08
Enrollment: 478
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: SCTV01C-02-1 is a randomized, double-blind, placebo controlled Phase Ⅰ/Ⅱ clinical trial of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant bivalent trimeric S protein vaccine manufactured by Sinocelltech, Ltd. The purpose of this study is to evaluate the safety , tolerability and immunogenicity of the experimental vaccine in healthy adults aged ≥ 18 Years previously unvaccinated.

Detailed description: This study is a randomized, double-blind, multi-center, placebo-controlled phase Ⅰ/Ⅱ clinical trial in adults aged ≥ 18 years previously unvaccinated. The purpose of this study is to evaluate the safety , tolerability and immunogenicity of the experimental SARS-CoV-2 protein vaccine (SCTV01C). The experimental vaccine and adjuvant (one placebo) were both manufactured by Sinocelltech, Ltd., while the saline (the other placebo) was commercially purchased. A total of 752 participants will be enrolled, with 112 at phase Ⅰ, and 640 at phase Ⅱ. There will be two dosage levels (20μg and 40μg), and two age groups (18\~59 years old and ≥ 60 years old ) at both Phase Ⅰ and Phase Ⅱ. All of participants will be assigned to receive two doses of experimental vaccine(20μg or 40μg) or placebo (Adjuvant or Saline) on the schedule of Day 0 and Day 28.

Eligibility criteria: Inclusion Criteria:

* Aged ≥18 years old when signing ICF;
* No other anti-SARS-COV-2 vaccines (approved for marketing or registered study) have been previously administered;
* Participants can sign written ICF and voluntarily participate in the study, and can fully understand the study procedure and the risk of participating in the study,
* Participants should have the ability to read, understand and fill the vaccination record card (VRC);
* Only for participants in Phase I : Those who are clinically judged to be healthy, the results of physical examination, vital signs and laboratory tests during the screening phase are normal;
* Only for participants in Phase II: Healthy participants or participants with stable underlying diseases;
* Fertile men and women of childbearing age voluntarily agree to take effective contraceptive measures from signing ICF to 6 months after full vaccination; the pregnancy test results of women of childbearing age are negative on screening.

Exclusion Criteria:

* Presence of fever within 72 h before vaccination (axillary temperature ≥ 37.3℃), or active tuberculosis, or in the acute phase of other diseases;
* A history of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), or other coronavirus infections or illness or relevant
* A history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema;
* A medical or family history of seizure, epilepsy, encephalopathy and psychosis;
* Immunocompromised patients suffering or suffered from immunodeficiency diseases, important organ diseases, or immune diseases, etc.;
* Long-term use of immunosuppressive or immunomodulatory drugs for 14 or more days within 6 months prior to study enrollment, or planned use of immunosuppressive or immunomodulatory drugs within 2 years after study enrollment. The use of inhaled and topical corticosteroid is permitted;
* For Phase I participants only: Previously or currently suffering from clinically significant cardiovascular diseases (except for the hypertension that can be controlled with drugs), or clinically significant disorders related to respiratory system, liver and kidney (except for light fatty liver), gastrointestinal system (except for chronic gastritis), endocrine system, blood and lymphatic system, metabolic and skeletal systems, or malignancies (except for skin basal cell carcinoma and carcinoma in-situ of cervix), that may affect the study assessment, or cause risks during the study vaccination, or interfere with the data interpretation as determined by the investigator; For Phase II participants only: Presence of severe or uncontrollable cardiovascular diseases, or severe or uncontrollable disorders related to endocrine system, blood and lymphatic system, liver and kidney, respiratory system, metabolic and skeletal systems, or malignancies (except for skin basal cell carcinoma and carcinoma in-situ of cervix);
* Contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders;
* Participants who received any immunoglobulin or blood products in the previous 3 months, or plan to receive similar products during the study;
* Participants who received other intervention investigational drugs within 1 month before the vaccination (Except for the participants in the saline control group participating in the clinical study of COVID-19 vaccine);
* Participants vaccinated with influenza vaccine within 14 days, or with other type of vaccines within 28 days before the vaccination;
* Those who donated blood or had blood loss (≥450 mL) within 3 months before the first dose vaccination or plan to donate blood during the study period;
* Those who are pregnant or breast-feeding;
* Those who plan to donate ovum or sperms during the study period;
* Those who cannot follow the study procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing;
* Those unsuitable for participating in the clinical study as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants;
* For Phase I participants only: those who are tested positive for hepatitis B virus (HBV), hepatitis C virus (HCV), syphilis or HIV in terms of etiology or serology; For Phase II participants only: those who are tested positive for HIV in terms of etiology or serology.

Primary outcomes:
measure: Phase I: Incidence and severity of adverse reactions (ARs) from Day 0 to Day 7 days after each dose of vaccination.
timeFrame: From Day 0 to Day 7 after each dose
measure: Phase II: Geometric mean titers (GMT) and seroconversion rate of total IgG antibody (ELISA method) against the SARS-CoV-2 Alpha, Beta and Delta variants on Day 14 after the second dose of vaccination;
timeFrame: Day 14 after the second dose of vaccination
measure: Phase II: GMT and seroconversion rate of neutralizing antibody (Live-virus neutralization assay) against the Alpha and Beta variants of SARS-CoV-2 on Day 14 after the second dose of vaccination;
timeFrame: Day 14 after the second dose of vaccination
measure: Phase II: GMT and seroconversion rate of neutralizing antibody (Pseudovirus neutralization assay) against the SARS-CoV-2 Alpha and Beta variants on Day 14 after the second dose of vaccination;
timeFrame: Day 14 after the second dose of vaccination
measure: Phase II: Incidence and severity of solicited AEs from Day 0 to Day 7 after each dose of vaccination;
timeFrame: Day 0 to Day 7 after each dose of vaccination
Secondary outcomes:
measure: Phase I: GMT and seroconversion rate of total IgG antibody (ELISA method) against the Alpha, Beta, Delta variants SARS-CoV-2 and T4-Foldon on Day 28 after the first dose of vaccination;
timeFrame: Day 28 after the first dose of vaccination
measure: Phase I: GMT and seroconversion rate of total IgG antibody (ELISA method) against the Alpha, Beta, Delta variants of SARS-CoV-2 and T4-Foldon on Day 14, Day 28, Day 90, Day 180 and Day 365 after the second dose of vaccination;
timeFrame: Day 14, Day 28, Day 90, Day 180 and Day 365 after the second dose of vaccination;
measure: Phase I: GMT and seroconversion rate of neutralizing antibody (Pseudovirus neutralization assay) against the Alpha and Beta variants of SARS-CoV-2 on Day 14, Day 28, Day 90, Day 180 and Day 365 after the second dose of vaccination;
timeFrame: Day 14, Day 28, Day 90, Day 180 and Day 365 after the second dose of vaccination
measure: Phase I: GMT and seroconversion rate of neutralizing antibody (Live-virus neutralization assay) against the Alpha and Beta variants of SARS-CoV-2 on Day 14, Day 28, Day 90, Day 180 and Day 365 after the second dose of vaccination;
timeFrame: Day 14, Day 28, Day 90, Day 180 and Day 365 after the second dose of vaccination
measure: Phase I: Number of IFN-γ positive (characterizing Th1) and IL-4 positive (characterizing Th2) T cell subpopulations 14 days and 90 days after the second dose of study vaccination;
timeFrame: Day 14 and Day 90 after the second dose of study vaccination
measure: Phase I: Incidence and severity of solicited adverse events (AEs) from Day 0 to Day 7 days after each dose of vaccination;
timeFrame: Day 0 to Day 7 days after each dose of vaccination
measure: Phase I: Incidence and severity of all unsolicited AEs Day 0 to Day 28 after each dose of vaccination;
timeFrame: Day 0 to Day 28 after each dose of vaccination
measure: Phase I: Incidence and severity of laboratory abnormalities related AEs on Day 3 after each dose of vaccination;
timeFrame: Day 3 after each dose of vaccination
measure: Phase I: Incidence and severity of serious adverse events (SAEs), adverse events of special interest (AESIs) and medically attended adverse events (MAAEs) within 365 days after each dose of vaccination;
timeFrame: within 365 days after each dose of vaccination
measure: Phase II: Incidence and severity of all unsolicited AEs Day 0 to Day 28 after each dose of vaccination;
timeFrame: Day 0 to Day 28 after each dose of vaccination
measure: Phase II: Incidence and severity of SAEs, AESIs, MAAEs within 365 days after each dose of vaccination;
timeFrame: within 365 days after each dose of vaccination
measure: Phase II: GMT and seroconversion rate of total IgG antibodies (ELISA method) against the Alpha, Beta and Delta variants of SARS-CoV-2 on Day 28, Day 90, Day 180 and Day 365 after the second dose of vaccination;
timeFrame: Day 28, Day 90, Day 180 and Day 365 after the second dose of vaccination
measure: Phase II: GMT of the neutralizing antibody titer (pseudoviral neutralization assay) against the Alpha and Beta variants of SARS-CoV-2 on Day 28, Day 90, Day 180 and Day 365 after the second dose of vaccination;
timeFrame: Day 28, Day 90, Day 180 and Day 365 after the second dose of vaccination
measure: Phase II: GMT and seroconversion rate of neutralizing antibody (Live-virus neutralization assay) against the SARS-CoV-2 Alpha and Beta variants on Day 28, Day 90, Day 180 and Day 365 after the second dose of vaccination;
timeFrame: Day 28, Day 90, Day 180 and Day 365 after the second dose of vaccination
measure: Phase II: GMT of neutralizing antibody titers (pseudoviral neutralization assay) on Day 14, Day 28, Day 90, Day 180 and D365 after the second vaccination for other variants, such as Delta, Lambda and Gamma, etc.
timeFrame: Day 14, Day 28, Day 90, Day 180 and D365 after the second vaccination
Other outcomes:
Locations:
city: Hefei
country: China
facility: Anhui Provincial Hospital
state: Anhui
city: Beijing
country: China
facility: Peking University First Hospital
state: Beijing
city: Beijing
country: China
facility: Beijing Tongren Hospital, CMU
state: Beijing
city: Langfang
country: China
facility: PetroChina Central Hospital
state: Hebei
city: Changsha
country: China
facility: Hunan Provincial Center for Disease Control And Prevention
state: Hunan
Study officials:
affiliation: Peking University First Hospital
name: Yimin Cui, M.D.
role: PRINCIPAL_INVESTIGATOR
References: